(Bloomberg) -- After Barry Robinson's bowel cancer spread to his lungs in January, doctors told the U.K. resident his life might be extended with ImClone Systems Inc.'s Erbitux.
Britain's National Health Service has refused to pay for the treatment, leaving the 60-year-old retired soldier to raise 20,000 pounds ($39,500) to purchase the drug. A U.K. agency ruled in January that the cost outweighed its benefits. Erbitux is the seventh cancer medicine the advisory panel has decided is too expensive in the past year.
Read more at Bloomberg Exclusive News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment